Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study

EuroIntervention 2012;8:109-116 publish online ahead of print January 2012. DOI: 10.4244/EIJV8I1A17

Gian Battista Danzi1*, MD; Bernard Chevalier2, MD; Philip Urban3, MD; Farzin Fath-Ordoubadi4, MD; Didier Carrie5, MD; Marcus Wiemer6, MD; Antonio Serra7, MD; William Wijns8, MD; Petr Kala9, MD; Amerigo Stabile10, MD; Javier Goicolea Ruigomez11, MD; Dragan Sagic12, MD; Peep Laanmets13, MD; Gerhard Strupp14, MD; Nick West15, MD; Dragica Paunovic16, MD; on behalf of NOBORI 2 Investigators

1.Ospedale Maggiore Policlinico, Milan, Italy; 2. Institut Cardiovasculaire Paris Sud, Massy/Quincy, France; 3. Hôpital de la Tour, Geneva, Switzerland; 4. Royal Infirmary, Manchester, United Kingdom; 5. Centre Hospitalier Universitaire

Aims: Previous studies for approved indications (on-label) have shown the good safety and efficacy profiles of the Nobori DES. We conducted a pr

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

clinical researchbiodegradable polymeroff-label indication

Share on Facebook Share on Twitter Share on Linkedin

Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study

Read next article

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke